News | August 02, 2013

Mercator Gains Patent for Micro-Infusion Drug Delivery for Renal Denervation

Mercator’s Micro-Infusion devices treat peripheral artery disease (PAD), other cardiovascular diseases and pulmonary disease, and deliver of stem cells


August 2, 2013 — Mercator MedSystems has been issued U.S. Patent 8,465,752, which protects the company’s sole U.S. rights to deliver drugs or other nerve modifying agents to tissue surrounding arteries for renal denervation (RDN). The system also can be used for carotid body modulation (CBM) procedures. 

These procedures, used to modulate or deaden hyperactive nerves, are designed to decrease uncontrolled hypertension, or high blood pressure, and are believed to be effective alternative therapies for the more than 12 million patients worldwide whose blood pressure remains uncontrolled – even with the use of three or more anti-hypertensive medications.

Mercator’s Micro-Infusion devices are currently used for treating peripheral artery disease (PAD), other cardiovascular diseases and pulmonary disease, and for the delivery of stem cells.

Mercator recently completed a clinical feasibility study at St. Catherine’s Hospital in Frankfurt, Germany to determine the effectiveness of lidocaine delivery, prior to energy-based renal denervation, as a means of alleviating or minimizing pain experienced with these procedures. Ablating or cauterizing the nerves lining the renal arteries with radio-frequency or ultrasound-equipped catheters often produces intense pain that is difficult to control – even with the use of systemic painkillers and morphine.  Four patients were pre-treated with promising results. 

After the procedures, one of St. Catherine’s treating physicians, Horst Sievert commented said, “I am impressed with the ease of delivery and the interactive visualization offered by Mercator’s Bullfrog Micro-Infusion device. While there is more work to be done, this appears to be a promising approach as a pre-treatment – and longer term, with a neuro-modulating drug, as an alternative approach to RDN.”

Mercator’s Bullfrog and Cricket Micro-Infusion devices are cleared for commercialization in Europe, the United States and Australia.  The Micro-Infusion approach was created in the labs of The University of California, Berkeley in 2000.

For more information: www.mercatormed.com


Related Content

News | Hypertension

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

Home April 01, 2024
Home
News | Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

Home March 18, 2024
Home
News | Hypertension

February 27, 2024 — Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the ...

Home February 27, 2024
Home
News | Hypertension

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

Home February 14, 2024
Home
News | Hypertension

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk ...

Home January 19, 2024
Home
News | Hypertension

December 13, 2023 —Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary ...

Home December 13, 2023
Home
News | Hypertension

December 7, 2023 — Indiana University School of Medicine researchers at the school’s South Bend regional campus, in ...

Home December 07, 2023
Home
News | Hypertension

November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...

Home November 15, 2023
Home
News | Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

Home September 22, 2023
Home
News | Hypertension

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

Home September 20, 2023
Home
Subscribe Now